Free Trial

Delcath Systems Q1 2024 Earnings Report

Delcath Systems logo
$13.16 -0.18 (-1.31%)
As of 12:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Delcath Systems EPS Results

Actual EPS
-$0.43
Consensus EPS
-$0.43
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Delcath Systems Revenue Results

Actual Revenue
$3.14 million
Expected Revenue
$3.70 million
Beat/Miss
Missed by -$560.00 thousand
YoY Revenue Growth
N/A

Delcath Systems Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Conference Call Audio

Remove Ads

Delcath Systems Earnings Headlines

Stop working weekends (do this 2-minute trick instead)
Since the pandemic, the average mortgage payment has jumped from $1,427 to $2,047. That's an extra $600 every single month just vanishing from people's pockets. Meanwhile, credit card debt is hitting record highs, and savings accounts are at their lowest since 2008. Most folks are left with two options… Get a second job... or work overtime on weekends. But what if there was a third option? I just uncovered a shocking anomaly in the options market that could change everything... One that lets you target extra cash on days when most people make nothing - weekends. Think what that could mean for your monthly budget...
BTIG Reaffirms Their Buy Rating on Delcath Systems (DCTH)
See More Delcath Systems Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Delcath Systems? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Delcath Systems and other key companies, straight to your email.

About Delcath Systems

Delcath Systems (NASDAQ:DCTH), an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

View Delcath Systems Profile

More Earnings Resources from MarketBeat